Literature DB >> 9778666

The apolipoprotein E epsilon 4 allele is associated with blunting of ketamine-induced psychosis in schizophrenia. A preliminary report.

A K Malhotra1, A Breier, D Goldman, L Picken, D Pickar.   

Abstract

Interindividual differences in the psychotomimetic response to the N-methyl-d-aspartate receptor antagonist ketamine are commonly observed. The apolipoprotein E (APOE) epsilon 4 allele has been associated with reduced severity of positive psychotic symptoms in schizophrenia. In this study, we sought to determine if the APOE epsilon 4 allele influences the psychotomimetic response to ketamine in schizophrenics. Eighteen patients genotyped at the APOE locus underwent a double-blind infusion of ketamine and of placebo. Ketamine-induced alterations in the brief psychiatric rating scale factors were compared between schizophrenics with and without the APOE epsilon 4 allele. APOE epsilon 4+ schizophrenics displayed significantly reduced ketamine-induced psychosis, as compared to epsilon 4-patients. These preliminary data indicate that the psychotomimetic response to ketamine may be genetically influenced and may provide additional evidence that APOE may modify expression of the positive symptoms in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9778666     DOI: 10.1016/S0893-133X(98)00031-1

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  8 in total

Review 1.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

2.  Greater vulnerability to the amnestic effects of ketamine in males.

Authors:  Celia J A Morgan; Edward B Perry; Hyung-Sang Cho; John H Krystal; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2006-08-01       Impact factor: 4.530

Review 3.  The neurobiology of apolipoproteins in psychiatric disorders.

Authors:  J Gregor Sutcliffe; Elizabeth A Thomas
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.590

Review 4.  Acute and chronic effects of ketamine upon human memory: a review.

Authors:  Celia J A Morgan; H Valerie Curran
Journal:  Psychopharmacology (Berl)       Date:  2006-09-28       Impact factor: 4.530

5.  Association of APOE E2 and low-density lipoprotein with depressive symptoms in Chinese senile schizophrenia inpatients: A cross-sectional study.

Authors:  Wei Li
Journal:  Schizophr Res Cogn       Date:  2020-11-19

Review 6.  Candidate gene studies of antipsychotic drug efficacy and drug-induced weight gain.

Authors:  Anil K Malhotra
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

7.  Dissecting the Syndrome of Schizophrenia: Progress toward Clinically Useful Biomarkers.

Authors:  Brian Dean
Journal:  Schizophr Res Treatment       Date:  2011-06-18

8.  Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Katherine Beck; Guy Hindley; Faith Borgan; Cedric Ginestet; Robert McCutcheon; Stefan Brugger; Naomi Driesen; Mohini Ranganathan; Deepak Cyril D'Souza; Matthew Taylor; John H Krystal; Oliver D Howes
Journal:  JAMA Netw Open       Date:  2020-05-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.